145 related articles for article (PubMed ID: 23394351)
21. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
22. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
Kewalramani T; Zelenetz AD; Teruya-Feldstein J; Hamlin P; Yahalom J; Horwitz S; Nimer SD; Moskowitz CH
Br J Haematol; 2006 Jul; 134(2):202-7. PubMed ID: 16759221
[TBL] [Abstract][Full Text] [Related]
23. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
24. Late relapse of Hodgkin's lymphoma - is it different in clinical characteristics and outcome?
Markovic O; Andjelic B; Tarabar O; Todorovic M; Filipovic B; Stanisavljevic D; Bila J; Antic D; Marisavljevic D; Mihaljevic B
J BUON; 2017; 22(2):481-486. PubMed ID: 28534373
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of Hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation.
Kaloyannidis P; Voutiadou G; Baltadakis I; Tsirigotis P; Spyridonidis A; Repousis P; Balta A; Tsimberis S; Karakasis D; Sakellari I; Dervenoulas I; Harhalakis N; Anagnostopoulos A
Biol Blood Marrow Transplant; 2012 Mar; 18(3):451-7. PubMed ID: 21803018
[TBL] [Abstract][Full Text] [Related]
26. Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma.
Hazar V; Kesik V; Aksoylar S; Karakukcu M; Ozturk G; Kupesiz A; Atas E; Oniz H; Kansoy S; Unal E; Tanyeli A; Erbey F; Elli M; Tacyildiz N; Karasu GT; Kocak U; Anak S; Yilmaz Bengoa S; Sezgin G; Atay D; Unal E; Uygun V; Kurucu N; Kaya Z; Yesilipek A;
Pediatr Transplant; 2015 Nov; 19(7):745-52. PubMed ID: 26346042
[TBL] [Abstract][Full Text] [Related]
27. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity.
Cohen S; Kiss T; Lachance S; Roy DC; Sauvageau G; Busque L; Ahmad I; Roy J
Biol Blood Marrow Transplant; 2012 Jun; 18(6):951-7. PubMed ID: 22155507
[TBL] [Abstract][Full Text] [Related]
28. [Autologous stem cell transplantation in patients with relapsed or refractory Hodgkin's disease].
Minigo H; Vrhovac R; Kalac M; Jaksić B
Acta Med Croatica; 2009 Jun; 63(3):215-7. PubMed ID: 19827348
[TBL] [Abstract][Full Text] [Related]
29. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
30. The timing of autologous stem cell transplantation and the prognostic factors affecting the prognosis in children with relapsed Hodgkin lymphoma.
Ataş E; Kesik V; Babacan O; Korkmazer N; Akyüz C
Pediatr Transplant; 2015 Jun; 19(4):380-4. PubMed ID: 25752654
[TBL] [Abstract][Full Text] [Related]
31. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
33. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
Lazarus HM; Loberiza FR; Zhang MJ; Armitage JO; Ballen KK; Bashey A; Bolwell BJ; Burns LJ; Freytes CO; Gale RP; Gibson J; Herzig RH; LeMaistre CF; Marks D; Mason J; Miller AM; Milone GA; Pavlovsky S; Reece DE; Rizzo JD; van Besien K; Vose JM; Horowitz MM
Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P
Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
[TBL] [Abstract][Full Text] [Related]
35. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.
Lieskovsky YE; Donaldson SS; Torres MA; Wong RM; Amylon MD; Link MP; Agarwal R
J Clin Oncol; 2004 Nov; 22(22):4532-40. PubMed ID: 15542804
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
[No Abstract] [Full Text] [Related]
37. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
38. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.
Bentolila G; Pavlovsky A
Leuk Lymphoma; 2020 Jul; 61(7):1548-1554. PubMed ID: 32148142
[TBL] [Abstract][Full Text] [Related]
39. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Torjman L; Ladeb S; Lakhal A; Ben Othman T; Abdelkefi A; Ben Abdeladhim A
Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
[TBL] [Abstract][Full Text] [Related]
40. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma.
Gordan LN; Sugrue MW; Lynch JW; Williams KD; Khan SA; Moreb JS
Bone Marrow Transplant; 2003 Jun; 31(11):1009-13. PubMed ID: 12774052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]